For triple positive metastatic breast cancer, is there a role for aromatase inhibitor + CDK 4/6 inhibitor with Her2 directed therapy in a patient that refuses chemotherapy?
Patient defers chemotherapy. She is currently on anastrozole/Herceptin and perjeta with a response but it is suboptimal. I would like to add a CDK 4/6 inhibitor.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Yale
Answered on
Recommend the PATINA trial, a randomized Phase 3 study. open to women or men with HR+, HER2+ metastatic breast cancer following completion of induction with anti-HER2-based chemotherapy. Would not recommend this approach outside of a clinical trial at this time, however.
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Sarah Cannon Cancer Institute at Menorah Medical Center
Answered on
I personally would not do it outside a clinical trial. I, on the other hand, would consider upgrading her endocrine treatment to fulvestrant.
Join for free or sign in to see the full answer